Big pharma partners flock to Adimab for antibodies
This article was originally published in Scrip
The already impressive list of companies that have partnered with the antibody technology firm Adimab has just got even longer. Biogen Idec and Novo Nordisk each signed up to milestone and royalty-based deals under which the four-year-old firm will identify fully human antibodies against two targets provided by its respective partners. Adimab also receives upfront payments from its partners.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.